MsC-CAR-T

Yuan Mao1, Yufeng Chen2, Xiaohui Yang3

  • 1Department of Geriatric Oncology, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China; National Health Commission Key Laboratory of Antibody Techniques, Nanjing Medical University, Nanjing, China; Department of Pathology, Nanjing Medical University, Nanjing, China; Jiangsu Province Engineering Research Center of Antibody Drug, Nanjing, China.

Cancer letters
|December 6, 2024
PubMed
概括

这项研究引入了针对MAGE-A1并分泌CD47阻断抗体的新型工程T细胞 (MsC1-CART). 这些细胞通过结合免疫疗法和免疫检查点阻塞,显示出治疗MAGE-A1阳性固体瘤的巨大潜力.